PHAXIAM publie aujourd’hui sa trésorerie au 30 juin 2023 et son calendrier financier pour le second semestre 2023.
PHAXIAM announces the implementation of the reverse share split of the shares composing the Company's share capital, by decision of the CEO on July 26th, 2023, following the sub-delegation granted…
PHAXIAM announces change of the mnemonic code of its share from ERYP to PHXM, following the merger between ERYTECH and PHERECYDES. The change has been notified by Euronext and will…
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical company developing innovative extended bacteriophage therapies to target antimicrobial resistance (AMR).
Erytech announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders…
The company reacts to a series of disinformation attempts by Akkadian Partners to try and destabilize ERYTECH.
Erytech announces that Akkadian Partners has initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual General Meeting on June 23.
ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 23, 2023 at 09:30am CEST at the Hôtel Intercontinental, 2 rue Scribe, 75009 Paris…